KFAS
TRVI icon

Keating Financial Advisory Services’s Trevi Therapeutics TRVI Stock Holding History

Keating Financial Advisory Services’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37 Buy
2
+1
+100% +$15 ﹤0.01% 2539
2026
Q1 		$12 Buy
+1
New +$11 ﹤0.01% 2539

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Keating Financial Advisory Services's TRVI Position: Q2 2026 in Review

Keating Financial Advisory Services increased its Trevi Therapeutics (TRVI) stake by 100% in Q2 2026, buying an estimated $15 and bringing the position to 2 shares worth $37. The position accounts for ﹤0.01% of the portfolio, ranked #2539.

Keating Financial Advisory Services first reported a position in TRVI in Q1 2026 and has held it in 2 quarters since. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Keating Financial Advisory Services held 2 shares of Trevi Therapeutics worth $37 as of Q2 2026.
  • Keating Financial Advisory Services bought 1 Trevi Therapeutics share in Q2 2026, an estimated $15.
  • Trevi Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2539 holding.
  • Keating Financial Advisory Services first reported a position in Trevi Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.